首页|复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化效果及安全性分析

复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化效果及安全性分析

扫码查看
目的 研究复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化效果及安全性.方法 选取浙江省台州医院2014年6月~2016年12年收治的100例乙肝后肝硬化患者为本次研究过程中研究对象,随机分为对照组和试验组2组,每组患者各为50例.对照组患者进行恩替卡韦治疗,试验组患者进行复方鳖甲软肝片联合恩替卡韦治疗.比较分析2组患者治疗效果与不良反应情况.结果试验组患者治疗有效率为90.0%.对照组治疗有效率为72.0%,试验组患者治疗有效率显著高于对照组,差异具有统计学意义(P<0.05).试验组呕吐2例,不良反应率为4.0%,对照组呕吐、头痛9例,不良反应率为18.0%.试验组不良反应率(4.0%)显著低于对照组(18.0%),差异具有统计学意义(P<0.05).结论 复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化临床效果较好,能够在一定程度上降低不良反应率,安全性较高,具有临床进一步推广和应用的意义.
Analysis on the effect and safety of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis
Objective To study the effect and safety of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis.Methods100 cases with hepatitis B cirrhosis in Zhejiang Taizhou hospital from June 2014 to December 2016 were selected as the research object in this study which were randomly divided into the control group and the experimental group 50 cases in each group.The control group were given entecavir, the experimental group were given compound Biejiaruangan tablets combined with entecavir.The clinical effect and the adverse reaction in the two groups were compared.ResultsThe effective rate was 90.0% in the experimental group, which was significantly higher than 72.0% in the control group(P<0.05).There were 2 patients vomiting in the experimental group, the adverse reaction rate was 4.0%.There were 9 cases of vomiting and headache in the control group, the adverse reaction rate was 18.0%.T,he adverse reaction rate(in the experimental group was significantly lower than that in the control group(P<0.05).ConclusionThe clinical effect of compound Biejiaruangan tablets combined with entecavir on the treatment of viral hepatitis B cirrhosis is better, which can reduce the rate of adverse reactions in a certain extent, is high safety, and worth popularizing.

compound Biejiaruangan tabletsentecavirviral hepatitis B cirrhosissafety

邵辉、陈晶艳、陈华忠

展开 >

浙江省台州医院 感染科,浙江 台州 317000

复方鳖甲软肝片 恩替卡韦 乙肝后肝硬化 安全性

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(6)
  • 14
  • 10